Price Target on US Biopharma Co. Boosted by $15
Source: Julian Harrison  (9/15/22)
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report. More >

New Drug Shown To Help Patients With Desmoid Tumors
Source: Dr. David Nierengarten  (9/15/22)
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report. More >

NDA for Dry Eye Disease Drug on Track for Q4/22 Submission
Source: Justin Kim   (9/15/22)
This and the biopharma's other treatment candidates for ocular diseases are underappreciated, which translates to an investment opportunity, noted an Oppenheimer report. More >

Co. Advancing Drug Class With Broad Potential
Source: Dr. Thomas Shrader   (9/13/22)
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report. More >

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'
Source: Clive Maund  (9/13/22)
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive. More >

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet
Source: Streetwise Reports  (9/12/22)
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run. More >

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise
Source: Dr. Jonathan Aschoff  (9/12/22)
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report. More >

US Co. To Regain All Rights to Its AGHD Diagnostic Test
Source: Dr. Ram Selvaraju  (9/8/22)
This is set to happen because the biopharma's commercialization partner recently terminated its agreement over the product, noted an H.C. Wainwright & Co. report. More >

Medtech Co. Meets Primary Endpoints in Ph. 3 Glaucoma Trials
Source: Streetwise Reports  (9/8/22)
Glaukos Corp.'s shares traded 18% higher yesterday after the company reported that in two separate Phase 3 trials, its iDose TR met its primary efficacy endpoints by lowering intraocular pressure in glaucoma patients. More >

Biopharma Co. Receives Approval From FDA Panel for ALS Drug
Source: Streetwise Reports  (9/8/22)
Amylyx Pharmaceuticals Inc.'s shares traded 51% higher after the company reported that a U.S. FDA advisory committee has voted to support approval of the firm's AMX0035 for use in treating amyotrophic lateral sclerosis. Although the committee's recommendation is not binding, it is expected that the decision will provide staunch support for approval of the firm's pending NDA for AMX0035, which has a target action date of September 29, 2022. More >

Biopharma Co. Transforming Injected Drugs Into Pills
Source: Dr. Ram Selvaraju  (9/7/22)
This Israeli firm recently attracted the attention of the US-based financial institution, H.C. Wainwright & Co., which launched analyst coverage of it. More >

Expert Says Life Science Corp.'s Technical Case Is Becoming Compelling
Source: Clive Maund  (9/7/22)
Expert Clive Maund shares his view on Awakn Life Sciences Corp. as its stock continues to strengthen. More >

Two Talks On New Cancer Drug Slated for Meeting This Week
Source: Dr. Tony Butler  (9/6/22)
The upcoming discussions pertain to a biopharma's clinical stage T-cell therapy as a treatment for solid tumors, noted a ROTH Capital Partners report. More >

Will Pharma Co. Keep Pushing Higher After Full Data Set Released on Lung Disease Study?
Source: Streetwise Reports  (9/4/22)
One small-cap pharma co. just published more good news on a possible treatment for patients suffering from idiopathic pulmonary fibrosis, a lung disease that's usually terminal. Find out why the company has more near-term catalysts and may continue to build on an 84% gain since a private placement in mid-August. More >

Denmark Co. To Buy US Biopharma Co. for $1.1 Billion
Source: Streetwise Reports  (9/2/22)
Forma Therapeutics Holdings Inc. shares traded 51% higher yesterday after the company reported it agreed to be acquired by Denmark's Novo Nordisk A/S in an all-cash deal for $20.00 per share. With the acquisition, Novo Nordisk aims to expand its global presence in the treatment of rare blood disorders and sickle cell disease. More >

Expert Rates Pharma Co. An Immediate Buy
Source: Chris Temple  (9/1/22)
Expert Chris Temple gives his view on Algernon Pharmaceuticals stock in light of its positive results for its Phase 2a study for the treatment of idiopathic pulmonary fibrosis and chronic cough. More >

FDA OKs Biopharma to Trial New Cell Therapy
Source: Mitchell Kapoor  (8/30/22)
Now with clearance, the firm plans to commence a Phase 1 study of its lead candidate in patients with lymphoma by the end of this year, noted an H.C. Wainwright & Co. report. More >

Pharma Co. Plans IND Filing for Dry Eye Disease Drug in Q4/22
  (8/30/22)
Shares of OKYO Pharma Ltd. traded 23% higher after the company reported it intends to submit an IND to the U.S. FDA for its OK-101 for treating dry eye disease in Q4/22. Together with its manufacturing partner, AmbioPharm Inc., the firm is now preparing to initiate a phase 2 clinical study in Q1/23. More >

Delay in New Drug Filing Now Could Yield Benefits Later
Source: Hartaj Singh  (8/29/22)
The developer of genetic medicines is taking six more months to conduct longer preclinical safety studies involving its lead therapeutic, noted an Oppenheimer report. More >

ACC Recommends Approved Drug for Lowering LDL
Source: Joseph Pantginis  (8/29/22)
This same medicine is currently being evaluated in a global clinical trial from which topline results are expected in Q1/23, noted an H.C. Wainwright & Co. report. More >

Pharma Co. To Provide HHS With Smallpox Drug
Source: Streetwise Reports  (8/29/22)
Chimerix Inc. shares traded 8% higher after the company reported it has entered into a 10-year, $680 million contract with a U.S. Government health agency to deliver up to 1.7 million treatment courses of its TEMBEXA for use as a medical countermeasure for smallpox. More >

Biotech Co. Signs Option Agreement With Drug Co. to Find Ideal Ketamine Formula
Source: Streetwise Reports  (8/26/22)
A small biotech has taken further steps to deepen the intellectual property moat for its potentially revolutionary treatment for alcohol addiction. Find out which company it is and why one analyst has given it a CA$8 target price. More >

First Data Due by Year End 2022 From Study of New HAE Drug
Source: Hartaj Singh  (8/24/22)
Management's ongoing execution is raising the biopharma's profile among investors, noted an Oppenheimer report. More >

New Schizophrenia Drug Has Chance of Getting FDA Approved
Source: Dr. Thomas Shrader   (8/24/22)
The U.S. Food and Drug Administration's follow-up to the new drug application for this potential treatment suggests a possible green light based on unmet medical need, noted a BTIG report. More >

Hedge Fund Doubles Position in Biotech Co.
Source: Streetwise Reports  (8/23/22)
A Canadian hedge fund doubled its stake in a tiny biotech that demonstrated promising results in a study that used a former Sanofi drug called Ifenprodil to treat idiopathic pulmonary fibrosis and chronic cough. Find out the name of the company and why one analyst has given it a 12-month CA$25 target price — a 560% increase from the unit price in its recent placement. More >